BioCardia reports positive echo results from Phase III HFrEF trial; reduced ventricular remodeling

BioCardia, Inc.

CardiAMP cell therapy reduced left ventricular end-diastolic volume (p=0.06) and end-systolic volume (p=0.09).
In patients with elevated NTproBNP, volume reductions were clinically meaningful and statistically significant (p=0.02, p=0.01).
Results correlated with reduced major adverse cardiovascular events and improved quality of life.
Echocardiography outcomes by Yale core lab; data presented at THT 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.